nodes	percent_of_prediction	percent_of_DWPC	metapath
Lurasidone—CYP3A4—Topotecan—lung cancer	0.0419	0.142	CbGbCtD
Lurasidone—CYP3A4—Gefitinib—lung cancer	0.0384	0.13	CbGbCtD
Lurasidone—CYP3A4—Teniposide—lung cancer	0.0372	0.126	CbGbCtD
Lurasidone—HTR2A—phrenic nerve—lung cancer	0.0306	0.324	CbGeAlD
Lurasidone—CYP3A4—Vinorelbine—lung cancer	0.0295	0.1	CbGbCtD
Lurasidone—CYP3A4—Crizotinib—lung cancer	0.0235	0.0796	CbGbCtD
Lurasidone—CYP3A4—Erlotinib—lung cancer	0.0227	0.0768	CbGbCtD
Lurasidone—CYP3A4—Paclitaxel—lung cancer	0.0208	0.0703	CbGbCtD
Lurasidone—CYP3A4—Irinotecan—lung cancer	0.0205	0.0694	CbGbCtD
Lurasidone—CYP3A4—Vinblastine—lung cancer	0.0182	0.0617	CbGbCtD
Lurasidone—HTR7—pulmonary artery—lung cancer	0.0178	0.188	CbGeAlD
Lurasidone—CYP3A4—Etoposide—lung cancer	0.0164	0.0555	CbGbCtD
Lurasidone—CYP3A4—Docetaxel—lung cancer	0.015	0.0508	CbGbCtD
Lurasidone—CYP3A4—Doxorubicin—lung cancer	0.0112	0.0379	CbGbCtD
Lurasidone—HTR2A—pulmonary artery—lung cancer	0.0111	0.117	CbGeAlD
Lurasidone—HTR7—respiratory system—lung cancer	0.00299	0.0317	CbGeAlD
Lurasidone—DRD2—respiratory system—lung cancer	0.00283	0.03	CbGeAlD
Lurasidone—HTR7—epithelium—lung cancer	0.0025	0.0265	CbGeAlD
Lurasidone—ADRA2C—bronchus—lung cancer	0.00226	0.024	CbGeAlD
Lurasidone—HTR7—trachea—lung cancer	0.00221	0.0234	CbGeAlD
Lurasidone—ADRA2C—trachea—lung cancer	0.00203	0.0215	CbGeAlD
Lurasidone—ADRA2C—cardiac atrium—lung cancer	0.00191	0.0202	CbGeAlD
Lurasidone—HTR2A—respiratory system—lung cancer	0.00187	0.0198	CbGeAlD
Lurasidone—ADRA2A—bronchus—lung cancer	0.00181	0.0191	CbGeAlD
Lurasidone—ADRA2A—trachea—lung cancer	0.00162	0.0172	CbGeAlD
Lurasidone—HTR7—lung—lung cancer	0.00159	0.0168	CbGeAlD
Lurasidone—HTR2A—epithelium—lung cancer	0.00156	0.0165	CbGeAlD
Lurasidone—ADRA2A—cardiac atrium—lung cancer	0.00152	0.0161	CbGeAlD
Lurasidone—DRD2—lung—lung cancer	0.0015	0.0159	CbGeAlD
Lurasidone—ADRA2C—lung—lung cancer	0.00146	0.0155	CbGeAlD
Lurasidone—HTR2A—trachea—lung cancer	0.00138	0.0146	CbGeAlD
Lurasidone—ADRA2A—lung—lung cancer	0.00116	0.0123	CbGeAlD
Lurasidone—ADRA2C—lymph node—lung cancer	0.000999	0.0106	CbGeAlD
Lurasidone—HTR2A—lung—lung cancer	0.000991	0.0105	CbGeAlD
Lurasidone—ADRA2A—lymph node—lung cancer	0.000797	0.00844	CbGeAlD
Lurasidone—Gastrointestinal disorder—Irinotecan—lung cancer	0.000357	0.000755	CcSEcCtD
Lurasidone—Hypertension—Paclitaxel—lung cancer	0.000356	0.000754	CcSEcCtD
Lurasidone—Fatigue—Irinotecan—lung cancer	0.000356	0.000754	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Etoposide—lung cancer	0.000356	0.000753	CcSEcCtD
Lurasidone—Pruritus—Vinorelbine—lung cancer	0.000354	0.00075	CcSEcCtD
Lurasidone—Mental disorder—Docetaxel—lung cancer	0.000352	0.000745	CcSEcCtD
Lurasidone—Myalgia—Paclitaxel—lung cancer	0.000352	0.000744	CcSEcCtD
Lurasidone—Hypotension—Cisplatin—lung cancer	0.000351	0.000741	CcSEcCtD
Lurasidone—Anxiety—Paclitaxel—lung cancer	0.00035	0.000741	CcSEcCtD
Lurasidone—Malnutrition—Docetaxel—lung cancer	0.00035	0.00074	CcSEcCtD
Lurasidone—Decreased appetite—Gemcitabine—lung cancer	0.00035	0.00074	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—lung cancer	0.000349	0.000738	CcSEcCtD
Lurasidone—Nausea—Topotecan—lung cancer	0.000348	0.000736	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Gemcitabine—lung cancer	0.000347	0.000735	CcSEcCtD
Lurasidone—Abdominal discomfort—Methotrexate—lung cancer	0.000347	0.000734	CcSEcCtD
Lurasidone—Fatigue—Gemcitabine—lung cancer	0.000347	0.000734	CcSEcCtD
Lurasidone—Nausea—Erlotinib—lung cancer	0.000344	0.000728	CcSEcCtD
Lurasidone—Dry mouth—Paclitaxel—lung cancer	0.000344	0.000727	CcSEcCtD
Lurasidone—Diarrhoea—Vinorelbine—lung cancer	0.000343	0.000725	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Cisplatin—lung cancer	0.000342	0.000723	CcSEcCtD
Lurasidone—Infection—Etoposide—lung cancer	0.000341	0.000722	CcSEcCtD
Lurasidone—Blood creatinine increased—Doxorubicin—lung cancer	0.00034	0.000719	CcSEcCtD
Lurasidone—Back pain—Docetaxel—lung cancer	0.000339	0.000716	CcSEcCtD
Lurasidone—Dysuria—Methotrexate—lung cancer	0.000339	0.000716	CcSEcCtD
Lurasidone—Neutropenia—Methotrexate—lung cancer	0.000339	0.000716	CcSEcCtD
Lurasidone—Gastrointestinal pain—Irinotecan—lung cancer	0.000338	0.000715	CcSEcCtD
Lurasidone—Muscle spasms—Docetaxel—lung cancer	0.000336	0.000712	CcSEcCtD
Lurasidone—Tachycardia—Etoposide—lung cancer	0.000335	0.00071	CcSEcCtD
Lurasidone—Infection—Paclitaxel—lung cancer	0.000335	0.000708	CcSEcCtD
Lurasidone—Dyspnoea—Cisplatin—lung cancer	0.000334	0.000707	CcSEcCtD
Lurasidone—Skin disorder—Etoposide—lung cancer	0.000334	0.000706	CcSEcCtD
Lurasidone—Erectile dysfunction—Methotrexate—lung cancer	0.000333	0.000705	CcSEcCtD
Lurasidone—Hyperhidrosis—Etoposide—lung cancer	0.000332	0.000703	CcSEcCtD
Lurasidone—Shock—Paclitaxel—lung cancer	0.000332	0.000701	CcSEcCtD
Lurasidone—Dizziness—Vinorelbine—lung cancer	0.000331	0.000701	CcSEcCtD
Lurasidone—Orthostatic hypotension—Doxorubicin—lung cancer	0.000331	0.000701	CcSEcCtD
Lurasidone—Abdominal pain upper—Doxorubicin—lung cancer	0.000331	0.000701	CcSEcCtD
Lurasidone—Nervous system disorder—Paclitaxel—lung cancer	0.00033	0.000699	CcSEcCtD
Lurasidone—Tachycardia—Paclitaxel—lung cancer	0.000329	0.000696	CcSEcCtD
Lurasidone—Breast disorder—Doxorubicin—lung cancer	0.000328	0.000693	CcSEcCtD
Lurasidone—Skin disorder—Paclitaxel—lung cancer	0.000327	0.000692	CcSEcCtD
Lurasidone—Abdominal pain—Irinotecan—lung cancer	0.000327	0.000691	CcSEcCtD
Lurasidone—Decreased appetite—Cisplatin—lung cancer	0.000326	0.00069	CcSEcCtD
Lurasidone—Hyperhidrosis—Paclitaxel—lung cancer	0.000326	0.000689	CcSEcCtD
Lurasidone—Nasopharyngitis—Doxorubicin—lung cancer	0.000324	0.000686	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Cisplatin—lung cancer	0.000324	0.000685	CcSEcCtD
Lurasidone—Anaemia—Docetaxel—lung cancer	0.000323	0.000684	CcSEcCtD
Lurasidone—Infestation NOS—Methotrexate—lung cancer	0.000323	0.000683	CcSEcCtD
Lurasidone—Infestation—Methotrexate—lung cancer	0.000323	0.000683	CcSEcCtD
Lurasidone—Hypotension—Etoposide—lung cancer	0.000321	0.000679	CcSEcCtD
Lurasidone—Gastritis—Doxorubicin—lung cancer	0.000321	0.000679	CcSEcCtD
Lurasidone—Alanine aminotransferase increased—Doxorubicin—lung cancer	0.00032	0.000677	CcSEcCtD
Lurasidone—Vomiting—Vinorelbine—lung cancer	0.000319	0.000674	CcSEcCtD
Lurasidone—Renal failure—Methotrexate—lung cancer	0.000317	0.000671	CcSEcCtD
Lurasidone—Rash—Vinorelbine—lung cancer	0.000316	0.000668	CcSEcCtD
Lurasidone—Dermatitis—Vinorelbine—lung cancer	0.000316	0.000668	CcSEcCtD
Lurasidone—Hypotension—Paclitaxel—lung cancer	0.000315	0.000666	CcSEcCtD
Lurasidone—Syncope—Docetaxel—lung cancer	0.000314	0.000664	CcSEcCtD
Lurasidone—Dysphagia—Doxorubicin—lung cancer	0.000313	0.000663	CcSEcCtD
Lurasidone—Influenza—Doxorubicin—lung cancer	0.000313	0.000663	CcSEcCtD
Lurasidone—Leukopenia—Docetaxel—lung cancer	0.000313	0.000663	CcSEcCtD
Lurasidone—Eosinophilia—Doxorubicin—lung cancer	0.00031	0.000656	CcSEcCtD
Lurasidone—Loss of consciousness—Docetaxel—lung cancer	0.000308	0.000651	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Paclitaxel—lung cancer	0.000307	0.000649	CcSEcCtD
Lurasidone—Dyspnoea—Etoposide—lung cancer	0.000306	0.000648	CcSEcCtD
Lurasidone—Somnolence—Etoposide—lung cancer	0.000306	0.000646	CcSEcCtD
Lurasidone—Angina pectoris—Doxorubicin—lung cancer	0.000305	0.000646	CcSEcCtD
Lurasidone—Hepatobiliary disease—Methotrexate—lung cancer	0.000305	0.000646	CcSEcCtD
Lurasidone—Insomnia—Paclitaxel—lung cancer	0.000305	0.000645	CcSEcCtD
Lurasidone—Convulsion—Docetaxel—lung cancer	0.000303	0.000641	CcSEcCtD
Lurasidone—Hypertension—Docetaxel—lung cancer	0.000302	0.000639	CcSEcCtD
Lurasidone—Agranulocytosis—Methotrexate—lung cancer	0.000301	0.000637	CcSEcCtD
Lurasidone—Dyspnoea—Paclitaxel—lung cancer	0.0003	0.000635	CcSEcCtD
Lurasidone—Somnolence—Paclitaxel—lung cancer	0.0003	0.000634	CcSEcCtD
Lurasidone—Decreased appetite—Etoposide—lung cancer	0.000299	0.000632	CcSEcCtD
Lurasidone—Myalgia—Docetaxel—lung cancer	0.000298	0.00063	CcSEcCtD
Lurasidone—Nausea—Vinorelbine—lung cancer	0.000298	0.000629	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Etoposide—lung cancer	0.000297	0.000628	CcSEcCtD
Lurasidone—Dyspepsia—Paclitaxel—lung cancer	0.000297	0.000627	CcSEcCtD
Lurasidone—Asthenia—Irinotecan—lung cancer	0.000296	0.000627	CcSEcCtD
Lurasidone—Fatigue—Etoposide—lung cancer	0.000296	0.000627	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	0.000296	0.000626	CcSEcCtD
Lurasidone—Dysuria—Doxorubicin—lung cancer	0.000293	0.00062	CcSEcCtD
Lurasidone—Neutropenia—Doxorubicin—lung cancer	0.000293	0.00062	CcSEcCtD
Lurasidone—Decreased appetite—Paclitaxel—lung cancer	0.000293	0.00062	CcSEcCtD
Lurasidone—Dry mouth—Docetaxel—lung cancer	0.000291	0.000616	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Paclitaxel—lung cancer	0.000291	0.000615	CcSEcCtD
Lurasidone—Fatigue—Paclitaxel—lung cancer	0.000291	0.000615	CcSEcCtD
Lurasidone—Asthenia—Gemcitabine—lung cancer	0.000289	0.000611	CcSEcCtD
Lurasidone—Urinary tract disorder—Methotrexate—lung cancer	0.000286	0.000605	CcSEcCtD
Lurasidone—Weight increased—Doxorubicin—lung cancer	0.000285	0.000603	CcSEcCtD
Lurasidone—Pruritus—Gemcitabine—lung cancer	0.000285	0.000602	CcSEcCtD
Lurasidone—Urethral disorder—Methotrexate—lung cancer	0.000284	0.000601	CcSEcCtD
Lurasidone—Infection—Docetaxel—lung cancer	0.000284	0.0006	CcSEcCtD
Lurasidone—Hyperglycaemia—Doxorubicin—lung cancer	0.000283	0.000598	CcSEcCtD
Lurasidone—Diarrhoea—Irinotecan—lung cancer	0.000283	0.000598	CcSEcCtD
Lurasidone—Gastrointestinal pain—Etoposide—lung cancer	0.000281	0.000594	CcSEcCtD
Lurasidone—Shock—Docetaxel—lung cancer	0.000281	0.000594	CcSEcCtD
Lurasidone—Nervous system disorder—Docetaxel—lung cancer	0.00028	0.000592	CcSEcCtD
Lurasidone—Infestation NOS—Doxorubicin—lung cancer	0.000279	0.000591	CcSEcCtD
Lurasidone—Infestation—Doxorubicin—lung cancer	0.000279	0.000591	CcSEcCtD
Lurasidone—Tachycardia—Docetaxel—lung cancer	0.000279	0.00059	CcSEcCtD
Lurasidone—Skin disorder—Docetaxel—lung cancer	0.000277	0.000587	CcSEcCtD
Lurasidone—Gastrointestinal pain—Paclitaxel—lung cancer	0.000276	0.000583	CcSEcCtD
Lurasidone—Diarrhoea—Gemcitabine—lung cancer	0.000275	0.000583	CcSEcCtD
Lurasidone—Renal failure—Doxorubicin—lung cancer	0.000275	0.000581	CcSEcCtD
Lurasidone—Dizziness—Irinotecan—lung cancer	0.000273	0.000578	CcSEcCtD
Lurasidone—Abdominal pain—Etoposide—lung cancer	0.000272	0.000575	CcSEcCtD
Lurasidone—Urinary tract infection—Doxorubicin—lung cancer	0.000272	0.000575	CcSEcCtD
Lurasidone—Eye disorder—Methotrexate—lung cancer	0.000271	0.000573	CcSEcCtD
Lurasidone—Asthenia—Cisplatin—lung cancer	0.000269	0.000569	CcSEcCtD
Lurasidone—Cardiac disorder—Methotrexate—lung cancer	0.000269	0.000569	CcSEcCtD
Lurasidone—Hypotension—Docetaxel—lung cancer	0.000267	0.000565	CcSEcCtD
Lurasidone—Abdominal pain—Paclitaxel—lung cancer	0.000266	0.000563	CcSEcCtD
Lurasidone—Hepatobiliary disease—Doxorubicin—lung cancer	0.000264	0.000559	CcSEcCtD
Lurasidone—Angiopathy—Methotrexate—lung cancer	0.000263	0.000556	CcSEcCtD
Lurasidone—Vomiting—Irinotecan—lung cancer	0.000263	0.000556	CcSEcCtD
Lurasidone—Agranulocytosis—Doxorubicin—lung cancer	0.000261	0.000552	CcSEcCtD
Lurasidone—Rash—Irinotecan—lung cancer	0.000261	0.000551	CcSEcCtD
Lurasidone—Dermatitis—Irinotecan—lung cancer	0.00026	0.000551	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Docetaxel—lung cancer	0.00026	0.00055	CcSEcCtD
Lurasidone—Insomnia—Docetaxel—lung cancer	0.000258	0.000546	CcSEcCtD
Lurasidone—Diarrhoea—Cisplatin—lung cancer	0.000257	0.000543	CcSEcCtD
Lurasidone—Vomiting—Gemcitabine—lung cancer	0.000256	0.000541	CcSEcCtD
Lurasidone—Bradycardia—Doxorubicin—lung cancer	0.000255	0.00054	CcSEcCtD
Lurasidone—Dyspnoea—Docetaxel—lung cancer	0.000255	0.000539	CcSEcCtD
Lurasidone—Somnolence—Docetaxel—lung cancer	0.000254	0.000537	CcSEcCtD
Lurasidone—Mental disorder—Methotrexate—lung cancer	0.000254	0.000537	CcSEcCtD
Lurasidone—Rash—Gemcitabine—lung cancer	0.000254	0.000537	CcSEcCtD
Lurasidone—Dermatitis—Gemcitabine—lung cancer	0.000254	0.000536	CcSEcCtD
Lurasidone—Malnutrition—Methotrexate—lung cancer	0.000252	0.000534	CcSEcCtD
Lurasidone—Dyspepsia—Docetaxel—lung cancer	0.000251	0.000532	CcSEcCtD
Lurasidone—Decreased appetite—Docetaxel—lung cancer	0.000248	0.000525	CcSEcCtD
Lurasidone—Urinary tract disorder—Doxorubicin—lung cancer	0.000248	0.000524	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Docetaxel—lung cancer	0.000247	0.000522	CcSEcCtD
Lurasidone—Asthenia—Etoposide—lung cancer	0.000247	0.000522	CcSEcCtD
Lurasidone—Connective tissue disorder—Doxorubicin—lung cancer	0.000247	0.000522	CcSEcCtD
Lurasidone—Fatigue—Docetaxel—lung cancer	0.000246	0.000521	CcSEcCtD
Lurasidone—Urethral disorder—Doxorubicin—lung cancer	0.000246	0.00052	CcSEcCtD
Lurasidone—Nausea—Irinotecan—lung cancer	0.000245	0.000519	CcSEcCtD
Lurasidone—Back pain—Methotrexate—lung cancer	0.000244	0.000516	CcSEcCtD
Lurasidone—Pruritus—Etoposide—lung cancer	0.000243	0.000514	CcSEcCtD
Lurasidone—Asthenia—Paclitaxel—lung cancer	0.000242	0.000511	CcSEcCtD
Lurasidone—Nausea—Gemcitabine—lung cancer	0.000239	0.000506	CcSEcCtD
Lurasidone—Vomiting—Cisplatin—lung cancer	0.000239	0.000505	CcSEcCtD
Lurasidone—Pruritus—Paclitaxel—lung cancer	0.000238	0.000504	CcSEcCtD
Lurasidone—Vision blurred—Methotrexate—lung cancer	0.000238	0.000503	CcSEcCtD
Lurasidone—Rash—Cisplatin—lung cancer	0.000237	0.0005	CcSEcCtD
Lurasidone—Dermatitis—Cisplatin—lung cancer	0.000236	0.0005	CcSEcCtD
Lurasidone—Diarrhoea—Etoposide—lung cancer	0.000235	0.000497	CcSEcCtD
Lurasidone—Eye disorder—Doxorubicin—lung cancer	0.000234	0.000496	CcSEcCtD
Lurasidone—Gastrointestinal pain—Docetaxel—lung cancer	0.000234	0.000494	CcSEcCtD
Lurasidone—Anaemia—Methotrexate—lung cancer	0.000233	0.000493	CcSEcCtD
Lurasidone—Cardiac disorder—Doxorubicin—lung cancer	0.000233	0.000493	CcSEcCtD
Lurasidone—Diarrhoea—Paclitaxel—lung cancer	0.000231	0.000488	CcSEcCtD
Lurasidone—Angiopathy—Doxorubicin—lung cancer	0.000228	0.000482	CcSEcCtD
Lurasidone—Malaise—Methotrexate—lung cancer	0.000227	0.000481	CcSEcCtD
Lurasidone—Dizziness—Etoposide—lung cancer	0.000227	0.000481	CcSEcCtD
Lurasidone—Vertigo—Methotrexate—lung cancer	0.000227	0.000479	CcSEcCtD
Lurasidone—Abdominal pain—Docetaxel—lung cancer	0.000226	0.000478	CcSEcCtD
Lurasidone—Leukopenia—Methotrexate—lung cancer	0.000226	0.000478	CcSEcCtD
Lurasidone—Arrhythmia—Doxorubicin—lung cancer	0.000224	0.000474	CcSEcCtD
Lurasidone—Dizziness—Paclitaxel—lung cancer	0.000223	0.000471	CcSEcCtD
Lurasidone—Nausea—Cisplatin—lung cancer	0.000223	0.000471	CcSEcCtD
Lurasidone—Mental disorder—Doxorubicin—lung cancer	0.00022	0.000465	CcSEcCtD
Lurasidone—Convulsion—Methotrexate—lung cancer	0.000219	0.000462	CcSEcCtD
Lurasidone—Vomiting—Etoposide—lung cancer	0.000219	0.000462	CcSEcCtD
Lurasidone—Malnutrition—Doxorubicin—lung cancer	0.000218	0.000462	CcSEcCtD
Lurasidone—Rash—Etoposide—lung cancer	0.000217	0.000458	CcSEcCtD
Lurasidone—Dermatitis—Etoposide—lung cancer	0.000216	0.000458	CcSEcCtD
Lurasidone—Flatulence—Doxorubicin—lung cancer	0.000215	0.000455	CcSEcCtD
Lurasidone—Myalgia—Methotrexate—lung cancer	0.000215	0.000454	CcSEcCtD
Lurasidone—Vomiting—Paclitaxel—lung cancer	0.000214	0.000453	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	0.000213	0.000451	CcSEcCtD
Lurasidone—Rash—Paclitaxel—lung cancer	0.000212	0.000449	CcSEcCtD
Lurasidone—Dermatitis—Paclitaxel—lung cancer	0.000212	0.000449	CcSEcCtD
Lurasidone—Back pain—Doxorubicin—lung cancer	0.000211	0.000447	CcSEcCtD
Lurasidone—Muscle spasms—Doxorubicin—lung cancer	0.00021	0.000444	CcSEcCtD
Lurasidone—Vision blurred—Doxorubicin—lung cancer	0.000206	0.000435	CcSEcCtD
Lurasidone—Asthenia—Docetaxel—lung cancer	0.000205	0.000433	CcSEcCtD
Lurasidone—Infection—Methotrexate—lung cancer	0.000205	0.000433	CcSEcCtD
Lurasidone—Nausea—Etoposide—lung cancer	0.000204	0.000432	CcSEcCtD
Lurasidone—Pruritus—Docetaxel—lung cancer	0.000202	0.000427	CcSEcCtD
Lurasidone—Nervous system disorder—Methotrexate—lung cancer	0.000202	0.000427	CcSEcCtD
Lurasidone—Anaemia—Doxorubicin—lung cancer	0.000202	0.000427	CcSEcCtD
Lurasidone—Agitation—Doxorubicin—lung cancer	0.000201	0.000425	CcSEcCtD
Lurasidone—Nausea—Paclitaxel—lung cancer	0.0002	0.000423	CcSEcCtD
Lurasidone—Skin disorder—Methotrexate—lung cancer	0.0002	0.000423	CcSEcCtD
Lurasidone—Hyperhidrosis—Methotrexate—lung cancer	0.000199	0.000421	CcSEcCtD
Lurasidone—Malaise—Doxorubicin—lung cancer	0.000197	0.000417	CcSEcCtD
Lurasidone—Vertigo—Doxorubicin—lung cancer	0.000196	0.000415	CcSEcCtD
Lurasidone—Syncope—Doxorubicin—lung cancer	0.000196	0.000414	CcSEcCtD
Lurasidone—Leukopenia—Doxorubicin—lung cancer	0.000196	0.000414	CcSEcCtD
Lurasidone—Diarrhoea—Docetaxel—lung cancer	0.000195	0.000413	CcSEcCtD
Lurasidone—Hypotension—Methotrexate—lung cancer	0.000192	0.000407	CcSEcCtD
Lurasidone—Loss of consciousness—Doxorubicin—lung cancer	0.000192	0.000406	CcSEcCtD
Lurasidone—Convulsion—Doxorubicin—lung cancer	0.000189	0.0004	CcSEcCtD
Lurasidone—Dizziness—Docetaxel—lung cancer	0.000189	0.0004	CcSEcCtD
Lurasidone—Hypertension—Doxorubicin—lung cancer	0.000189	0.000399	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Methotrexate—lung cancer	0.000188	0.000397	CcSEcCtD
Lurasidone—Insomnia—Methotrexate—lung cancer	0.000186	0.000394	CcSEcCtD
Lurasidone—Myalgia—Doxorubicin—lung cancer	0.000186	0.000393	CcSEcCtD
Lurasidone—Anxiety—Doxorubicin—lung cancer	0.000185	0.000392	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	0.000185	0.000391	CcSEcCtD
Lurasidone—Dyspnoea—Methotrexate—lung cancer	0.000184	0.000388	CcSEcCtD
Lurasidone—Somnolence—Methotrexate—lung cancer	0.000183	0.000387	CcSEcCtD
Lurasidone—Dry mouth—Doxorubicin—lung cancer	0.000182	0.000385	CcSEcCtD
Lurasidone—Vomiting—Docetaxel—lung cancer	0.000182	0.000384	CcSEcCtD
Lurasidone—Dyspepsia—Methotrexate—lung cancer	0.000181	0.000383	CcSEcCtD
Lurasidone—Rash—Docetaxel—lung cancer	0.00018	0.000381	CcSEcCtD
Lurasidone—Dermatitis—Docetaxel—lung cancer	0.00018	0.000381	CcSEcCtD
Lurasidone—Decreased appetite—Methotrexate—lung cancer	0.000179	0.000379	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Methotrexate—lung cancer	0.000178	0.000376	CcSEcCtD
Lurasidone—Fatigue—Methotrexate—lung cancer	0.000177	0.000375	CcSEcCtD
Lurasidone—Infection—Doxorubicin—lung cancer	0.000177	0.000375	CcSEcCtD
Lurasidone—Shock—Doxorubicin—lung cancer	0.000175	0.000371	CcSEcCtD
Lurasidone—Nervous system disorder—Doxorubicin—lung cancer	0.000175	0.00037	CcSEcCtD
Lurasidone—Tachycardia—Doxorubicin—lung cancer	0.000174	0.000368	CcSEcCtD
Lurasidone—Skin disorder—Doxorubicin—lung cancer	0.000173	0.000366	CcSEcCtD
Lurasidone—Hyperhidrosis—Doxorubicin—lung cancer	0.000172	0.000365	CcSEcCtD
Lurasidone—Nausea—Docetaxel—lung cancer	0.00017	0.000359	CcSEcCtD
Lurasidone—Gastrointestinal pain—Methotrexate—lung cancer	0.000168	0.000356	CcSEcCtD
Lurasidone—Hypotension—Doxorubicin—lung cancer	0.000167	0.000352	CcSEcCtD
Lurasidone—Abdominal pain—Methotrexate—lung cancer	0.000163	0.000344	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Doxorubicin—lung cancer	0.000162	0.000344	CcSEcCtD
Lurasidone—Insomnia—Doxorubicin—lung cancer	0.000161	0.000341	CcSEcCtD
Lurasidone—Dyspnoea—Doxorubicin—lung cancer	0.000159	0.000336	CcSEcCtD
Lurasidone—Somnolence—Doxorubicin—lung cancer	0.000158	0.000335	CcSEcCtD
Lurasidone—Dyspepsia—Doxorubicin—lung cancer	0.000157	0.000332	CcSEcCtD
Lurasidone—Decreased appetite—Doxorubicin—lung cancer	0.000155	0.000328	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Doxorubicin—lung cancer	0.000154	0.000326	CcSEcCtD
Lurasidone—Fatigue—Doxorubicin—lung cancer	0.000154	0.000325	CcSEcCtD
Lurasidone—Asthenia—Methotrexate—lung cancer	0.000148	0.000312	CcSEcCtD
Lurasidone—Gastrointestinal pain—Doxorubicin—lung cancer	0.000146	0.000308	CcSEcCtD
Lurasidone—Pruritus—Methotrexate—lung cancer	0.000146	0.000308	CcSEcCtD
Lurasidone—Abdominal pain—Doxorubicin—lung cancer	0.000141	0.000298	CcSEcCtD
Lurasidone—Diarrhoea—Methotrexate—lung cancer	0.000141	0.000298	CcSEcCtD
Lurasidone—Dizziness—Methotrexate—lung cancer	0.000136	0.000288	CcSEcCtD
Lurasidone—Vomiting—Methotrexate—lung cancer	0.000131	0.000277	CcSEcCtD
Lurasidone—Rash—Methotrexate—lung cancer	0.00013	0.000275	CcSEcCtD
Lurasidone—Dermatitis—Methotrexate—lung cancer	0.00013	0.000274	CcSEcCtD
Lurasidone—Asthenia—Doxorubicin—lung cancer	0.000128	0.000271	CcSEcCtD
Lurasidone—Pruritus—Doxorubicin—lung cancer	0.000126	0.000267	CcSEcCtD
Lurasidone—Nausea—Methotrexate—lung cancer	0.000122	0.000259	CcSEcCtD
Lurasidone—Diarrhoea—Doxorubicin—lung cancer	0.000122	0.000258	CcSEcCtD
Lurasidone—Dizziness—Doxorubicin—lung cancer	0.000118	0.000249	CcSEcCtD
Lurasidone—Vomiting—Doxorubicin—lung cancer	0.000113	0.00024	CcSEcCtD
Lurasidone—Rash—Doxorubicin—lung cancer	0.000112	0.000238	CcSEcCtD
Lurasidone—Dermatitis—Doxorubicin—lung cancer	0.000112	0.000238	CcSEcCtD
Lurasidone—Nausea—Doxorubicin—lung cancer	0.000106	0.000224	CcSEcCtD
Lurasidone—HTR7—Signaling Pathways—EP300—lung cancer	1.66e-05	0.000121	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—PIK3CD—lung cancer	1.66e-05	0.000121	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—GSTT1—lung cancer	1.65e-05	0.00012	CbGpPWpGaD
Lurasidone—ADRA2C—GPCR downstream signaling—PIK3CA—lung cancer	1.64e-05	0.000119	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—MAPK3—lung cancer	1.64e-05	0.000119	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—CYP2A6—lung cancer	1.63e-05	0.000119	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—GCLC—lung cancer	1.63e-05	0.000119	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—POMC—lung cancer	1.63e-05	0.000118	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—KRAS—lung cancer	1.62e-05	0.000118	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—SRC—lung cancer	1.62e-05	0.000117	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—MAPK3—lung cancer	1.61e-05	0.000117	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PIK3CD—lung cancer	1.61e-05	0.000117	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—BRAF—lung cancer	1.61e-05	0.000117	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—POMC—lung cancer	1.6e-05	0.000117	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—ALB—lung cancer	1.59e-05	0.000116	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—IL6R—lung cancer	1.59e-05	0.000116	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CREBBP—lung cancer	1.59e-05	0.000115	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—BRAF—lung cancer	1.58e-05	0.000115	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—VEGFA—lung cancer	1.57e-05	0.000114	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—IL6R—lung cancer	1.56e-05	0.000114	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CREBBP—lung cancer	1.56e-05	0.000114	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—EGFR—lung cancer	1.56e-05	0.000113	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—STAT3—lung cancer	1.56e-05	0.000113	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—NRAS—lung cancer	1.55e-05	0.000113	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—ENO1—lung cancer	1.55e-05	0.000112	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—PIK3CA—lung cancer	1.54e-05	0.000112	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—MDM2—lung cancer	1.54e-05	0.000112	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—EGFR—lung cancer	1.53e-05	0.000112	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PIK3CG—lung cancer	1.53e-05	0.000111	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—KIT—lung cancer	1.53e-05	0.000111	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—APC—lung cancer	1.53e-05	0.000111	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—NRAS—lung cancer	1.53e-05	0.000111	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—RAF1—lung cancer	1.53e-05	0.000111	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—MAP2K1—lung cancer	1.51e-05	0.00011	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—EGF—lung cancer	1.51e-05	0.00011	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—ERBB2—lung cancer	1.51e-05	0.00011	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—PIK3CD—lung cancer	1.5e-05	0.000109	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—MTOR—lung cancer	1.49e-05	0.000109	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—PIK3CB—lung cancer	1.49e-05	0.000109	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—PTEN—lung cancer	1.49e-05	0.000109	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—PIK3CA—lung cancer	1.49e-05	0.000108	CbGpPWpGaD
Lurasidone—DRD2—GPCR downstream signaling—PIK3CA—lung cancer	1.49e-05	0.000108	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—MAP2K1—lung cancer	1.49e-05	0.000108	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—MAPK3—lung cancer	1.49e-05	0.000108	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—MDM2—lung cancer	1.49e-05	0.000108	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—PIK3CD—lung cancer	1.48e-05	0.000108	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—RAF1—lung cancer	1.48e-05	0.000108	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—KRAS—lung cancer	1.47e-05	0.000107	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—MAPK3—lung cancer	1.47e-05	0.000107	CbGpPWpGaD
Lurasidone—HTR2A—GPCR downstream signaling—PIK3CA—lung cancer	1.47e-05	0.000107	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—ERBB2—lung cancer	1.46e-05	0.000107	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—POMC—lung cancer	1.46e-05	0.000106	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—KRAS—lung cancer	1.45e-05	0.000105	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—MYC—lung cancer	1.45e-05	0.000105	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—MTOR—lung cancer	1.45e-05	0.000105	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—PIK3CB—lung cancer	1.45e-05	0.000105	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—BRAF—lung cancer	1.44e-05	0.000105	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CXCL8—lung cancer	1.44e-05	0.000104	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—HRAS—lung cancer	1.43e-05	0.000104	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—EP300—lung cancer	1.42e-05	0.000104	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—IL6R—lung cancer	1.42e-05	0.000103	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CREBBP—lung cancer	1.42e-05	0.000103	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—EGFR—lung cancer	1.42e-05	0.000103	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PIK3CB—lung cancer	1.4e-05	0.000102	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—EGFR—lung cancer	1.4e-05	0.000102	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PTGS2—lung cancer	1.39e-05	0.000101	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CXCL8—lung cancer	1.39e-05	0.000101	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—CYP2E1—lung cancer	1.39e-05	0.000101	CbGpPWpGaD
Lurasidone—HTR1A—GPCR downstream signaling—AKT1—lung cancer	1.39e-05	0.000101	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—HRAS—lung cancer	1.38e-05	0.0001	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CASP3—lung cancer	1.37e-05	9.99e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—IL2—lung cancer	1.37e-05	9.98e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—NQO1—lung cancer	1.37e-05	9.97e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—IL6—lung cancer	1.36e-05	9.93e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—MAP2K1—lung cancer	1.36e-05	9.86e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—PIK3CA—lung cancer	1.35e-05	9.84e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—MDM2—lung cancer	1.35e-05	9.8e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PIK3CD—lung cancer	1.35e-05	9.79e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—RAF1—lung cancer	1.34e-05	9.77e-05	CbGpPWpGaD
Lurasidone—ADRA2C—GPCR downstream signaling—AKT1—lung cancer	1.34e-05	9.76e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—KRAS—lung cancer	1.34e-05	9.73e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CCND1—lung cancer	1.34e-05	9.72e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—JUN—lung cancer	1.33e-05	9.7e-05	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR downstream signaling—PIK3CA—lung cancer	1.33e-05	9.7e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—PIK3CA—lung cancer	1.33e-05	9.68e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CASP3—lung cancer	1.33e-05	9.67e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—ERBB2—lung cancer	1.33e-05	9.66e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—IL2—lung cancer	1.33e-05	9.65e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—MDM2—lung cancer	1.33e-05	9.65e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—RAF1—lung cancer	1.32e-05	9.61e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—IL6—lung cancer	1.32e-05	9.6e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—KRAS—lung cancer	1.32e-05	9.59e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—MTOR—lung cancer	1.31e-05	9.54e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—PIK3CB—lung cancer	1.31e-05	9.54e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—ERBB2—lung cancer	1.31e-05	9.51e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—MMP9—lung cancer	1.3e-05	9.44e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CCND1—lung cancer	1.29e-05	9.41e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CDKN1A—lung cancer	1.29e-05	9.41e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—JUN—lung cancer	1.29e-05	9.39e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—PTEN—lung cancer	1.29e-05	9.39e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—PIK3CB—lung cancer	1.29e-05	9.38e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—MTOR—lung cancer	1.29e-05	9.38e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CXCL8—lung cancer	1.26e-05	9.17e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—AKT1—lung cancer	1.26e-05	9.16e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—MMP9—lung cancer	1.26e-05	9.14e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—HRAS—lung cancer	1.25e-05	9.11e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CDKN1A—lung cancer	1.25e-05	9.1e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—PTEN—lung cancer	1.25e-05	9.08e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CXCL8—lung cancer	1.24e-05	9.02e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—STK11—lung cancer	1.24e-05	8.99e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—HRAS—lung cancer	1.23e-05	8.96e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—EP300—lung cancer	1.23e-05	8.95e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—PIK3CA—lung cancer	1.23e-05	8.94e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—AKT1—lung cancer	1.22e-05	8.86e-05	CbGpPWpGaD
Lurasidone—DRD2—GPCR downstream signaling—AKT1—lung cancer	1.22e-05	8.85e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PTEN—lung cancer	1.21e-05	8.82e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—PIK3CA—lung cancer	1.21e-05	8.81e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—MDM2—lung cancer	1.21e-05	8.77e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CASP3—lung cancer	1.21e-05	8.77e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—IL2—lung cancer	1.2e-05	8.76e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—RAF1—lung cancer	1.2e-05	8.74e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—IL6—lung cancer	1.2e-05	8.72e-05	CbGpPWpGaD
Lurasidone—HTR2A—GPCR downstream signaling—AKT1—lung cancer	1.2e-05	8.71e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—SRC—lung cancer	1.2e-05	8.7e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—EP300—lung cancer	1.19e-05	8.66e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—ERBB2—lung cancer	1.19e-05	8.65e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—TP53—lung cancer	1.19e-05	8.64e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CASP3—lung cancer	1.19e-05	8.63e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—IL2—lung cancer	1.18e-05	8.62e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—IL6—lung cancer	1.18e-05	8.58e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CCND1—lung cancer	1.17e-05	8.54e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—MTOR—lung cancer	1.17e-05	8.54e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PIK3CB—lung cancer	1.17e-05	8.54e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—JUN—lung cancer	1.17e-05	8.52e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—VEGFA—lung cancer	1.17e-05	8.48e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—SRC—lung cancer	1.16e-05	8.42e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—EP300—lung cancer	1.16e-05	8.41e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CCND1—lung cancer	1.16e-05	8.4e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—STAT3—lung cancer	1.15e-05	8.39e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—JUN—lung cancer	1.15e-05	8.38e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—NRAS—lung cancer	1.15e-05	8.37e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—GSTP1—lung cancer	1.14e-05	8.32e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—MMP9—lung cancer	1.14e-05	8.29e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—HRAS—lung cancer	1.14e-05	8.27e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CDKN1A—lung cancer	1.14e-05	8.26e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—PTEN—lung cancer	1.13e-05	8.24e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CXCL8—lung cancer	1.13e-05	8.2e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—VEGFA—lung cancer	1.13e-05	8.2e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—MMP9—lung cancer	1.12e-05	8.16e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—HRAS—lung cancer	1.12e-05	8.15e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CDKN1A—lung cancer	1.12e-05	8.13e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—STAT3—lung cancer	1.12e-05	8.12e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—PTEN—lung cancer	1.11e-05	8.11e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—NRAS—lung cancer	1.11e-05	8.1e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—CAT—lung cancer	1.11e-05	8.1e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—AKT1—lung cancer	1.11e-05	8.04e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—MAPK3—lung cancer	1.1e-05	8.02e-05	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR downstream signaling—AKT1—lung cancer	1.09e-05	7.93e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—IL6—lung cancer	1.09e-05	7.91e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—AKT1—lung cancer	1.09e-05	7.91e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—ABCB1—lung cancer	1.08e-05	7.88e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—EP300—lung cancer	1.08e-05	7.86e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CASP3—lung cancer	1.08e-05	7.85e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—IL2—lung cancer	1.08e-05	7.84e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—IL6—lung cancer	1.07e-05	7.8e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—MYC—lung cancer	1.07e-05	7.8e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—MAPK3—lung cancer	1.07e-05	7.76e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—TYMS—lung cancer	1.06e-05	7.73e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—EP300—lung cancer	1.06e-05	7.73e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—PIK3CA—lung cancer	1.05e-05	7.66e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—GSTM1—lung cancer	1.05e-05	7.65e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CCND1—lung cancer	1.05e-05	7.64e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—SRC—lung cancer	1.05e-05	7.64e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—EGFR—lung cancer	1.05e-05	7.63e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—JUN—lung cancer	1.05e-05	7.63e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—MYC—lung cancer	1.04e-05	7.55e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—SRC—lung cancer	1.03e-05	7.52e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—VEGFA—lung cancer	1.02e-05	7.44e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—MMP9—lung cancer	1.02e-05	7.42e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CDKN1A—lung cancer	1.02e-05	7.39e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—EGFR—lung cancer	1.02e-05	7.38e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PTEN—lung cancer	1.01e-05	7.38e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—STAT3—lung cancer	1.01e-05	7.37e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—NRAS—lung cancer	1.01e-05	7.35e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—VEGFA—lung cancer	1.01e-05	7.32e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—AKT1—lung cancer	1e-05	7.3e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—STAT3—lung cancer	9.97e-06	7.25e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—CYP1A1—lung cancer	9.97e-06	7.25e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—NRAS—lung cancer	9.95e-06	7.23e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—KRAS—lung cancer	9.91e-06	7.21e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—AKT1—lung cancer	9.9e-06	7.2e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—ERCC2—lung cancer	9.88e-06	7.19e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—MAPK3—lung cancer	9.68e-06	7.04e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—EP300—lung cancer	9.67e-06	7.04e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—KRAS—lung cancer	9.59e-06	6.97e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—MAPK3—lung cancer	9.53e-06	6.93e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—MYC—lung cancer	9.42e-06	6.85e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—SRC—lung cancer	9.41e-06	6.84e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—MYC—lung cancer	9.27e-06	6.74e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—EGFR—lung cancer	9.21e-06	6.7e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—VEGFA—lung cancer	9.16e-06	6.66e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—PIK3CA—lung cancer	9.1e-06	6.62e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—STAT3—lung cancer	9.07e-06	6.6e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—EGFR—lung cancer	9.06e-06	6.59e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—NRAS—lung cancer	9.05e-06	6.58e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—PIK3CA—lung cancer	8.81e-06	6.41e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—TP53—lung cancer	8.81e-06	6.41e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—KRAS—lung cancer	8.7e-06	6.33e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—MAPK3—lung cancer	8.67e-06	6.3e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—AKT1—lung cancer	8.61e-06	6.26e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—KRAS—lung cancer	8.56e-06	6.23e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PIK3CA—lung cancer	8.56e-06	6.22e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—APOA1—lung cancer	8.55e-06	6.22e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—TP53—lung cancer	8.52e-06	6.2e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—MYC—lung cancer	8.43e-06	6.13e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—HRAS—lung cancer	8.42e-06	6.13e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—EGFR—lung cancer	8.24e-06	6e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—HRAS—lung cancer	8.15e-06	5.93e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—IL6—lung cancer	8.06e-06	5.86e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—PIK3CA—lung cancer	7.99e-06	5.81e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—PIK3CA—lung cancer	7.87e-06	5.72e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PIK3CG—lung cancer	7.81e-06	5.68e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—IL6—lung cancer	7.8e-06	5.67e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—KRAS—lung cancer	7.79e-06	5.66e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—TP53—lung cancer	7.73e-06	5.62e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—TP53—lung cancer	7.61e-06	5.53e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—AKT1—lung cancer	7.44e-06	5.41e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—POMC—lung cancer	7.43e-06	5.4e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—HRAS—lung cancer	7.4e-06	5.38e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—HRAS—lung cancer	7.28e-06	5.29e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—CREBBP—lung cancer	7.24e-06	5.26e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—AKT1—lung cancer	7.2e-06	5.23e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PIK3CA—lung cancer	7.16e-06	5.2e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—IL6—lung cancer	7.08e-06	5.15e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—AKT1—lung cancer	6.99e-06	5.08e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—IL6—lung cancer	6.96e-06	5.07e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—TP53—lung cancer	6.92e-06	5.03e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PIK3CD—lung cancer	6.86e-06	4.99e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—ALB—lung cancer	6.77e-06	4.93e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—HRAS—lung cancer	6.62e-06	4.82e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—AKT1—lung cancer	6.53e-06	4.75e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—AKT1—lung cancer	6.43e-06	4.67e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—IL6—lung cancer	6.34e-06	4.61e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PIK3CB—lung cancer	5.98e-06	4.35e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PTGS2—lung cancer	5.93e-06	4.31e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—AKT1—lung cancer	5.85e-06	4.25e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PTEN—lung cancer	5.17e-06	3.76e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—EP300—lung cancer	4.93e-06	3.58e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PIK3CA—lung cancer	3.65e-06	2.65e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—AKT1—lung cancer	2.98e-06	2.17e-05	CbGpPWpGaD
